SCHEMBL4649476

SCHEMBL4649476

CC(C)(C)OC(=O)N1CCC(CC(=O)N2CCC(O)CC2)CC1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 1/20 0.50
CRBN Q96SW2 1/20 0.50
HPGD P15428 1/20 0.48
KDM4E B2RXH2 1/20 0.47
PKM P14618 1/20 0.47
GLS O94925 2/20 0.46
RECQL P46063 1/20 0.46
EPHX1 P07099 1/20 0.46
FNTA P49354 2/20 0.45
FNTB P49356 2/20 0.45
SFRP1 Q8N474 1/20 0.45
TPSAB1 Q15661 1/20 0.44
TPSD1 Q9BZJ3 1/20 0.44
TPSG1 Q9NRR2 1/20 0.44
USP2 O75604 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
GPR119 Q8TDV5 2/20 0.44
FAAH O00519 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13812235 0.90 HPGD (0.60) DDB1CRBNHPGDKDM4EPKM
SCHEMBL9238271 0.88 KDM4E (0.50) DDB1CRBNHPGDKDM4EPKM
SCHEMBL21182317 0.88 DDB1 (0.42) DDB1CRBNHPGDKDM4EPKM
Ethane SCHEMBL897978 0.86 HPGD (0.60) HPGDKDM4ERECQLEPHX1USP2
SCHEMBL47319 0.86 HPGD (0.60) HPGDKDM4ERECQLEPHX1USP2
SCHEMBL9236069 0.86 KDM4E (0.48) DDB1CRBNHPGDKDM4EPKM
SCHEMBL13812230 0.86 DDB1 (0.48) DDB1CRBNHPGDKDM4EPKM
SCHEMBL4195097 0.86 KDM4E (0.48) DDB1CRBNHPGDKDM4EPKM
SCHEMBL13812227 0.85 DDB1 (0.47) DDB1CRBNHPGDKDM4EPKM
SCHEMBL1148424 0.84 HPGD (0.58) HPGDKDM4ERECQLEPHX1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111868031-B Process for the preparation of N-alkoxycarbonylpiperidine derivatives and intermediates therefor 有机合成药品工业株式会社 2023-10-03 CN disclosed
EP-3741745-B1 METHOD FOR PRODUCING N-ALKOXYCARBONYLPIPERIDINE DERIVATIVE, AND INTERMEDIATE THEREFOR YUKI GOSEI YAKUHIN KOGYO KK (JP) 2023-04-26 EP disclosed
US-11332458-B2 Method for preparing N-alkoxycarbonylpiperidine derivative, and intermediate therefor YUKI GOSEI KOGYO CO., LTD. (JP) 2022-05-17 US disclosed
US-20210122729-A1 METHOD FOR PRODUCING N-ALKOXYCARBONYLPIPERIDINE DERIVATIVE, AND INTERMEDIATE THEREFOR YUKI GOSEI KOGYO CO., LTD. (JP) 2021-04-29 US disclosed
EP-3741745-A1 METHOD FOR PRODUCING N-ALKOXYCARBONYLPIPERIDINE DERIVATIVE, AND INTERMEDIATE THEREFOR Yuki Gosei Kogyo Co., Ltd. (JP) 2020-11-25 EP disclosed
CN-111868031-A Process for producing N-alkoxycarbonylpiperidine derivative and intermediate therefor 有机合成药品工业株式会社 2020-10-30 CN disclosed
WO-2019142900-A1 METHOD FOR PRODUCING N-ALKOXYCARBONYLPIPERIDINE DERIVATIVE, AND INTERMEDIATE THEREFOR 有機合成薬品工業株式会社 2019-07-25 WO disclosed
EP-1400511-B1 Methods of producing n-alkoxycarbonylpiperidine derivatives and intermediates therefor YUKI GOSEI YAKUHIN KOGYO KK (JP) 2008-09-03 EP disclosed
US-6900326-B2 Method of producing N-alkoxycarbonylpiperidine derivative, new compound as raw material therefor, and method of producing the compound YUKI GOSEI KOGYO CO., LTD. (JP) 2005-05-31 US disclosed
US-20040063953-A1 Method of producing N-alkoxycarbonylpiperidine derivative, new compound as raw material therefor, and method of producing the compound YUKI GOSEI KOGYO CO., LTD. (JP) 2004-04-01 US disclosed
EP-1400511-A1 Methods of producing n-alkoxycarbonylpiperidine derivatives and intermediates therefor YUKI GOSEI KOGYO CO., LTD. (JP) 2004-03-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11332458-B2 Method for preparing N-alkoxycarbonylpiperidine derivative, and intermediate therefor ALDH7A1, FAR1, ADH1C DDB1 4779/4885CRBN 3901/4885HPGD 276/4885
US-20210122729-A1 METHOD FOR PRODUCING N-ALKOXYCARBONYLPIPERIDINE DERIVATIVE, AND INTERMEDIATE THEREFOR ALDH7A1, FAR1, ACSL1 DDB1 4802/4885CRBN 4048/4885HPGD 205/4885
US-20040063953-A1 Method of producing N-alkoxycarbonylpiperidine derivative, new compound as raw material therefor, and method of producing the compound ORMDL3, MRPS18A, ACSL3 DDB1 4310/4885CRBN 2854/4885HPGD 2553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.